Clinical trials
Phase 4 Metabolic Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Unknown status | 4 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 2 |
| Washington University School of Medicine | 2 |
| Baskent University | 1 |
| Dong-A ST Co., Ltd. | 1 |
| I.R.C.C.S. Fondazione Santa Lucia | 1 |
| Kirby Institute | 1 |
| Lo.Li.Pharma s.r.l | 1 |
| Massachusetts General Hospital | 1 |
| Nordsjaellands Hospital | 1 |
| Novartis Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Metabolic Diseases | 19 |
| Diabetes Mellitus, Type 2 | 7 |
| Diabetes Mellitus | 5 |
| Glucose Metabolism Disorders | 5 |
| Insulin Resistance | 4 |
| Endocrine System Diseases | 3 |
| Cardiovascular Diseases | 2 |
| Dyslipidemias | 2 |
| Kidney Diseases | 2 |
| Autoimmune Diseases | 1 |
Trials
Showing 51 to 19 of 19. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.